Accelerate Diagnostics downgraded by Craig-Hallum with a new price target
$AXDX
Biotechnology: Laboratory Analytical Instruments
Industrials
Craig-Hallum downgraded Accelerate Diagnostics from Buy to Hold and set a new price target of $5.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/9/2022 | $5.00 | Buy → Hold | Craig-Hallum |
4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
TUCSON, Ariz., Nov. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the third quarter ended September 30, 2024. "We are excited by the momentum we're building across our innovation pipeline, underscored by the successful launch of the clinical trial for our WAVETM system and the Gram-Negative assay. This quarter also marked a significant milestone with FDA clearance of our Accelerate ArcTM system, a testament to our commitment to breakthrough solutions in diagnostics," commented Jack Phillips, President and CEO of Accel
TUCSON, Ariz., Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m. Eastern Time to review 2024 third quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 1269422. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call will
An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from positive blood culture samples TUCSON, Ariz., Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper® CA System (MBT-CA System) and MBT-CA Sepsityper® software extension.
Gainers OneMedNet (NASDAQ:ONMD) stock moved upwards by 15.6% to $1.7 during Thursday's after-market session. The company's market cap stands at $40.5 million. 23andMe Holding (NASDAQ:ME) shares increased by 11.85% to $0.57. The company's market cap stands at $275.2 million. As per the news, the Q4 earnings report came out today. Biora Therapeutics (NASDAQ:BIOR) stock moved upwards by 10.0% to $0.55. The market value of their outstanding shares is at $19.7 million. Cue Health (NASDAQ:HLTH) shares moved upwards by 9.54% to $0.1. The company's market cap stands at $16.4 million. Accelerate Diagnostics (NASDAQ:AXDX) shares increased by 9.01% to $1.39. The market value of their outstanding s
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock increased by 84.3% to $2.34 during Tuesday's regular session. The market value of their outstanding shares is at $10.2 million. Genelux (NASDAQ:GNLX) shares increased by 28.6% to $5.53. The company's market cap stands at $149.2 million. Novo Integrated Sciences (NASDAQ:NVOS) shares moved upwards by 24.55% to $0.54. The market value of their outstanding shares is at $10.3 million. Bionomics (NASDAQ:BNOX) shares rose 23.93% to $1.14. The company's market cap stands at $12.1 million. Xylo Technologies (NASDAQ:XYLO) shares rose 21.98% to $2.33. The market value of their outstanding shares is at $4.4 million. Accelerate Diagnostics (NASDAQ
Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.72) by 22.22 percent. This is a 48.54 percent increase over losses of $(1.71) per share from the same period last year. The company reported quarterly sales of $2.921 million which missed the analyst consensus estimate of $3.000 million by 2.63 percent. This is a 3.88 percent increase over sales of $2.812 million the same period last year.
Craig-Hallum downgraded Accelerate Diagnostics from Buy to Hold and set a new price target of $5.00
TUCSON, Ariz., Nov. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the third quarter ended September 30, 2024. "We are excited by the momentum we're building across our innovation pipeline, underscored by the successful launch of the clinical trial for our WAVETM system and the Gram-Negative assay. This quarter also marked a significant milestone with FDA clearance of our Accelerate ArcTM system, a testament to our commitment to breakthrough solutions in diagnostics," commented Jack Phillips, President and CEO of Accel
TUCSON, Ariz., Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m. Eastern Time to review 2024 third quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 1269422. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call will
TUCSON, Ariz., Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced financial results for the second quarter ended June 30, 2024. "During the quarter we completed our pre-clinical trial demonstrating strong analytical performance of our WAVETM System and Gram-Negative Positive Blood Culture (PBC) assay. We are pleased to announce our pre-clinical trial was a success," commented Jack Phillips, President and CEO of Accelerate Diagnostics, Inc. "Additionally, we were able to raise an additional $15 million with certain existing noteholders, whic
SC 13G - Accelerate Diagnostics, Inc (0000727207) (Subject)
SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)
SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)
10-Q - Accelerate Diagnostics, Inc (0000727207) (Filer)
8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)
TUCSON, Ariz., March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO), effective March 31, 2023. David Patience, who previously served as Senior Director - Head of Business Development and Strategic Finance has been named as the company's new CFO, effective April 1, 2023. Reichling, who has been with the company since 2012, played a vital role in Accelerate Diagnostics' growth and success over the years. Dur
TUCSON, Ariz., March 8, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the company's board of directors effective February 22, 2023. Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, stated, "I am excited for Hany to step into this very important role as Chairman. Hany brings a wealth of leadership and strategic vision, focused on diagnostics and infectious disease testing, which is vital as we grow our
4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)
4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)